4D Molecular Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview

4D Molecular Therapeutics

03/11/2023 12:18

* 4D Molecular Therapeutics Inc  FDMT.OQ   FDMT.O  is
expected
to show a rise in quarterly revenue when it reports  results 
    * The Emeryville California-based  company is expected to
report 
a 1,505.9% increase in revenue to $8.029 million from $500
thousand a year ago, according to the mean estimate from 8
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for 4D Molecular
Therapeutics
Inc is for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $32​, above​ its last closing price
of $10.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.80       -0.81      -0.77     Beat    4.7
 Mar. 31 2023  -0.90       -0.89      -0.88     Beat    1.6
 Dec. 31 2022  -0.83       -0.79      -0.84     Missed  -6.9​
 Sep. 30 2022  -0.88       -0.91      -0.79     Beat    13.4
 ​​Jun.        -0.87       -0.85      -0.87     Missed  -2.4
 30 2022                                                
 Mar. 31 2022  -0.78       -0.81      -0.82     Missed  -1.2​
 Dec. 31 2021  -0.85       -0.86      -0.85     Beat    1.2
 Sep. 30 2021  -0.83       -0.80      -0.82     Missed  -1.9
 This summary was machine generated November 3 at 12:18 GMT.  All
figures in US dollars  unless otherwise stated